The general use of thyroid hormone and in particular FT4 levels as rational targets for replacement therapy for primary hypothyroidism would unify the targets with those of secondary hypothyroidism where already thyroid hormone levels are the recommended parameters to monitor (1, 57). The gene discussed is TG; the disease is isolated thyroid-stimulating hormone deficiency.